Consumer Site
Two women embracing outdoors with a Deplin logo overlay.
Healthcare Professionals

See how DEPLIN® helps with depression care

Nutrient demands that cannot be addressed by changes in diet alone can disrupt neurotransmitter-related pathways and affect how the brain responds to antidepressant treatment. Clinical nutritional support helps establish the biological foundation needed for care. DEPLIN® products support these pathways from the start, helping build the conditions the brain relies on throughout treatment.2
View DEPLIN® Formulas
View Clinical Impact Data
See how to Prescribe
Contact a DEPLIN® Rep

Why Consider DEPLIN®

Addresses nutrient needs that diet alone cannot meet in depression
Delivers bioactive L-methylfolate to aid neurotransmitter balance1
Expands support with vitamin D3, zinc, and L-theanine in DeplinPRO Mood Health™
Supports the biological foundation involved in treatment response
Complements standard antidepressant therapy
Clinically studied nutrients shown to be safe and well-tolerated10,29-33

Two DEPLIN® Formulas to Address Neurotransmitter Imbalance in Depression

DeplinPRO Mood Health™ builds on the nutritional foundation of DEPLIN® to support additional factors that affect depression.
Two bottles of Deplin on a purple background with text about depression support.

The Role of Nutrition in Depression Care

In depression, genetic and metabolic factors can lead to nutrient insufficiencies—such as low folate, vitamin D₃, and zinc—that disrupt neurotransmitter pathways and cannot be corrected through changes in diet alone. These disruptions can limit how the brain engages with antidepressant treatment and may increase side-effect burden, underscoring the need to restore the biochemical foundation required for effective treatment response.2
Learn more

How DEPLIN® Works

DEPLIN® products provide L-methylfolate—with DeplinPRO Mood Health™ providing additional nutrients—to help restore neurotransmitter balance and modulate glutamate levels in the brain. This can enhance the brain's natural ability to regulate mood and cognition, setting the foundation for effective depression treatment response.

In a person without depression

Mood regulation involves complex interactions between neurotransmitters such as glutamate, GABA, serotonin, dopamine, and norepinephrine.1,3-5,10 These neurotransmitters work together to maintain emotional balance and cognitive function.1,10

During Depression

The brain experiences deficits in neurotransmitter synthesis and imbalances in key systems. 1,6,8,13 Depression is also linked to oxidative stress, inflammation, impaired stress response, and reduced neural plasticity, all of which can worsen with nutrient deficiencies.1,5,7-9,35-37,40

Depression treatment

Conventional antidepressants influence the activity of available neurotransmitters to manage symptoms, but they do not restore the full biochemical balance required for optimal neurotransmitter function.1,14

With DeplinPRO Mood Health™

DeplinPRO Mood Health™ helps restore neurotransmitter homeostasis by addressing nutrient deficiencies to support key biochemical pathways, helping to enhance the antidepressant response.1,3,6,8,10,13,32
Explore Deplin Products

Your Partner in Depression Care

The DEPLIN® brand has been supporting patients with depression for more than 15 years. It’s the #1 prescribed medical food brand for depression* and DEPLIN® products can be used as part of depression care for patients aged 12 years and older.
More Resources
Become a Prescriber

Deplin FC™ is a medical food specially formulated to meet the distinctive nutritional requirements for neurotransmitter imbalances in the clinical dietary management of depression and schizophrenia. Use under medical supervision.

DeplinPRO Mood Health™ is a medical food specially formulated to meet the distinctive nutritional requirements for neurotransmitter imbalances in the clinical dietary management of mood disorders. Use under medical supervision.

†Deplin FC™ (FC for “free & clear”) and DeplinPRO Mood Health™are free from major allergens: milk, eggs, fish or shellfish, sesame, tree nuts, peanuts, wheat, and soy.

*Based on US dollar sales through IQVIA NSP reporting channels from January 2023 – December 2024 of Deplin® branded medical foods compared to other branded medical foods indicated for depression.

§Actual testimonials but pictures and names are for illustrative purposes only.

  1. Liwinski T, Lang UE. Nutrients. 2023;15(17):3859.
  2. Mrozek W, et al. Nutrition. 2023:112143.
  3. Shelton RC, et al. Primary Care Companion for CNS Disorders. 2013;15:1-9.
  4. Martami F, et al. Nutrients. 2023;15:3952.
  5. Piao M, et al. Neuropsychiatry (London). 2017;7:378-386.
  6. Anglin RE. The British Journal of Psychiatry. 2013;202:100-107.
  7. Berridge MJ. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2016;371:20150434.
  8. Yosaee S, et al. General Hospital Psychiatry. 2022;74:110- 117.
  9. Li MY, et al. Frontiers in Nutrition. 2022;9:853846. (original 34)
  10. Hidese S, et al. Nutrients. 2019;11:2362.
  11. Lehrer MH, et al. Psychoneuroendocrinology. 2020;113:104510.
  12. Roffman LJ, et al. Molecular Psychiatry. 2018;23:316-322.
  13. Mikola T, et al. Critical Reviews in Food Science and Nutrition. 2023;63(33):11784-11801.
  14. Andrews PW, et al. Frontiers in Psychology, 2012;24:117.
  15. Bender A, et al. Journal of Psychiatric Research. 2017;95:9-18.
  16. Li Z, et al. Journal of Affective Disorders. 2018;228:68-74. (original 44)
  17. Maxfield L, et al. Zinc deficiency. In: StatPearls [Internet]. StatPearls Publishing. 2023. https://www.ncbi.nlm.nih.gov/books/NBK493231/. Accessed October 21, 2025.
  18. Jain R, et al. CNS Spectrums. 2020;25(6):750-764.
  19. Wang JT, et al. Lancet. 2010;376(9736):180-188.
  20. Medline. Vitamin D deficiency. https://medlineplus.gov/vitaminddeficiency.html?utm_source=mplusconnect&utm_medium=application. Accessed October 21, 2025.
  21. Abdollahi S, et al. Advances in Nutrition. 2020;11:398-411
  22. Medline. Folate deficiency. https://medlineplus.gov/ency/article/000354.htm. Accessed October 21, 2025.
  23. Araujo JR, et al. Ageing Research Reviews. 2015;22:9-19.
  24. Gibson A, et al. QJM: Monthly Journal of the Association of Physicians. 2008;101(11):881-887.
  25. Wijnia JW, et al. Alcoholism: Clinical and Experimental Research. 2013;37(S1):E209-E215.
  26. Shere M, et al. Journal of Obstetrics and Gynaecology Canada. 2015;37(5):430-438.
  27. Huang HL, et al. Biomedical Reports. 2016;5:413-416.
  28. Wulffele MG, et al. Journal of Internal Medicine. 2003;254:455-463.
  29. Papakostas G, et al. Am J Psychiatry. 2012;169:1267-1274.
  30. Yosaee S, et al. Nutrition. 2020;71:110601.
  31. Evans M, et al. Neurology and Therapy. 2021;10:1061-1078.
  32. Zajecka JM, et al. Journal of Clinical Psychiatry. 2016;77(5):654-660.
  33. Wang T, et al. Evidence-Based Practice in Child and Adolescent Mental Health. 2024;9(1):119-137.(original 39)
  34. Ghaseminejad-Raeini A, et al. Frontiers in Immunology. 2023;14:950465.
  35. Krajewska M, et al. Frontiers in Endocrinology. 2022;13:920340.
  36. Hoepner CT, et al. Nutrients. 2021;13:767.
  37. Sun R, et al. Biomolecules. 2022;12:1000
  38. Miodownik C, et al. Clinical Neuropharmacology. 2011:34(4):155-160.
  39. Sakamato FL, et al. Pharmacological Research. 2019;147:104395.
  40. Qiu W, et al. Journal of Neuroendocrinology. 2019;31(10):e12787.
  41. Gammoh OS, Bashatwah R. Electronic Journal of General Medicine. 2023;20(5):em513.
  42. Szalach LP, et al. Archivum Immunologiae et Therapiae Experimentalis. 2019;67:143-151.
  43. Willems FF, et al. British Journal of Pharmacology. 2004;141:825-830.
  44. Kaviani M, et al. Journal of Affective Disorders. 2020;269:28-35.
  45. Finn R. Innophos. Chelamax® Zinc Bisglycinate: A Superior Alternative to Traditional Zinc. Solubility Whitepaper.
  46. Finn R. Innophos. Chelamax®: Chelated Minerals Show Increased Absorption. Absorption Whitepaper.
  47. Ranjbar E, et al. Nutritional Neuroscience. 2014;17(2):65-71.